A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.
- 1 October 1986
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 4 (10), 1455-1461
- https://doi.org/10.1200/jco.1986.4.10.1455
Abstract
Long-term follow-up results of two studies using cyclophosphamide, doxorubicin, vincristine, and prednisone plus bleomycin (CHOP-Bleo) for the treatment of diffuse large-cell lymphoma are presented. Twenty-eight patients were treated with conventional-dose CHOP-Bleo and 36 patients with maximally tolerated doses of CHOP-Bleo. The maximal duration of follow-up was 10.5 years. The minimum follow-up was 5.7 years. Seventy-five percent of the conventional-dose group achieved a complete remission (CR) with a 10-year actuarial survival of 53% and a corresponding relapse-free survival (RFS) of 69% for CRs. Eighty-one percent of the high-dose group achieved CR, and the 10-year actuarial survival for all patients and RFS for CRs were 48% and 63%, respectively. The combined actuarial survival and RFS for both groups were 51% and 66%, respectively, at 10 years. For 11 patients with stage III disease, 91% achieved CR, 52% survived at 10 years, and the RFS was 67% for CRs. Seventy-five percent of 44 patients with stage IV disease achieved CR, 50% survived at 10 years, and the RFS was 67% for CRs. Three of the 16 relapses occurred late, between 30 to 65 months after initiation of therapy. Neuropathy occurred in 14 patients (22%). Five patients (8%) died of complications related to treatment. Five (8%) had clinically apparent, but nonfatal cardiopulmonary complications. The CHOP-Bleo regimen is an effective treatment for diffuse large-cell lymphoma, and is moderately well tolerated. The use of high-dose CHOP-Bleo for induction therapy did not result in any advantage after long-term follow-up.This publication has 9 references indexed in Scilit:
- MACOP-B Chemotherapy for the Treatment of Diffuse Large-Cell LymphomaAnnals of Internal Medicine, 1985
- Stage IV diffuse large-cell lymphoma: a long-term analysis.Journal of Clinical Oncology, 1985
- Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP ChemotherapyAnnals of Internal Medicine, 1983
- Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic typeAmerican Journal Of Medicine, 1983
- IMVP-16 - AN EFFECTIVE REGIMEN FOR PATIENTS WITH LYMPHOMA WHO HAVE RELAPSED AFTER INITIAL COMBINATION CHEMOTHERAPY1982
- Protected environment-prophylactic antibiotic program for malignant lymphomaAmerican Journal Of Medicine, 1979
- COMBINATION CHEMOTHERAPY (CHOP-BLEO) IN ADVANCED (NON-HODGKIN) MALIGNANT-LYMPHOMA1977
- COMBINATION CHEMOTHERAPY OF ADVANCED NON-HODGKIN LYMPHOMA WITH BLEOMYCIN, ADRIAMYCIN, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (BACOP)1977
- Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) Combination Chemotherapy in the Treatment of Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1976